Salute e Benessere

SciBase has signed a Collaboration and License Agreement with Castle Biosciences…

"This collaboration with Castle Biosciences is exciting for SciBase," said Pia Renaudin, CEO of SciBase. "It will accelerate the use of Nevisense within the skin barrier health market. It will rapidly broaden our already existing clinical studies pipeline by increasing the number of studies, ultimately speeding up access to more effective therapies for patients with skin barrier dysfunction. We are also pleased to welcome Castle as a shareholder in SciBase." "This…
PR Newswire
17/06/2025

Implantica announces successful UK RefluxStop™ Users Meeting addressing growing…

Founder and CEO of Implantica, Dr. Peter Forsell, adds, "We sincerely thank and appreciate the world-leading healthcare policy advisory body, UK NICE, for their extensive and thorough review and announcement of the final positive recommendations for the RefluxStop™ procedure. Given how rampant GERD is in the UK, with up to 20% of the adult population struggling with the persistent discomfort and pain from the disease, the NICE recommendations for RefluxStop procedure couldn't be more…
PR Newswire
17/06/2025

Invitation to presentation of Essity's interim report for quarter 2, 2025

Contact information for conference call with the possibility to ask questions:UK: +44 (0) 33 0551 02 00 USA: +1 786 697 35 01SWE: +46 (0)8 505 204 24Please call in well in advance of the start of the presentation. Indicate: "Essity". Contact information for conference call with the possibility to ask questions: UK: +44 (0) 33 0551 02 00 USA : +1 786 697 35 01 SWE: +46 (0)8 505 204 24 Please call in well in advance of the start of the presentation. Indicate…
PR Newswire
17/06/2025

Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens…

TECNIS Odyssey IOL enables surgeons to deliver consistent and reliable patient outcomes.∫7,15 TECNIS Odyssey IOL enables surgeons to deliver consistent and reliable patient outcomes.∫7,15 This content is intended for Healthcare Professionals only, not for the general public. JACKSONVILLE, Fla. , June 17, 2025 /PRNewswire/ -- Johnson & Johnson, §a global leader in eye health, announced today that it is expanding its portfolio of presbyopia-correcting intraocular lenses...
PR Newswire
17/06/2025

STRENGTHENING OF DMS GROUP'S GOVERNANCE STRUCTURE: APPOINTMENT OF JULIEN DELPECH…

June 17, 2025 – 8:00 am – Diagnostic Medical Systems (Euronext Growth Paris: FR0012202497 – ALDMS and FR001400IAQ8 – DMSBS), a specialist in high-performance medical imaging systems for digital radiology and bone densitometry, announces the strengthening of its governance structure. At the Annual General Meeting of June 16, 2025, the shareholders…
Actusnews Wire
17/06/2025

Orion and Glykos announce the extension of their research collaboration and…

ORION CORPORATIONPRESS RELEASE17 JUNE 2025 at 9.00 EEST Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs Orion Corporation and Glykos Finland Oy today announced that they have extended their research collaboration and licensing agreement for the development of next-generation antibody-drug conjugates (ADCs). Under the extended agreement, Orion gains access to Glykos’ proprietary ADC...
Nasdaq GlobeNewswire
17/06/2025

ONWARD Medical Builds Commercial Momentum for the ARC-EX System and Reinforces…

Commercial traction:Following FDA market authorization, the Company met its Q1 objective for the limited initial phase of its US launch of the ARC-EX ®System, hiring, training and deploying a field organization, establishing a sales and service process, building a roster of reference clinics, and selling ten systems.Technology advancement:The Company’s investigational ARC-IM ®and ARC-BCI ®platforms reached new milestones with the 4 thand 5 thsuccessful BCI implants to...
Nasdaq GlobeNewswire
17/06/2025

Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress

Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Continued progress in advancing varoglutamstat in kidney disease based on encouraging data and expansion of IP portfolioVaroglutamstat’s pre-clinical dataset showing synergistic effect in combination with an SGLT-2 inhibitor in different treatment regimensNovel composition of matter patent for varoglutamstat granted after accelerated review in the U.S.; patent term to provide exclusivity through 2044...
Nasdaq GlobeNewswire
17/06/2025

International Pharmaceuticals, Inc. Partners with Anchanto to Power E-commerce…

With a wide portfolio of essential health and wellness products, IPI has long been a household name in the Philippines. As the company strengthens its presence in the digital commerce landscape, it recognized the need for a robust and reliable solution to streamline order processing, marketplace integrations, and inventory visibility. With a wide portfolio of essential health and wellness products, IPI has long been a household name inthe Philippines. As the company strengthens its presence...
PR Newswire
17/06/2025

Chronic Lower Back Pain Market to Expand Significantly During the Forecast…

In 2023, there were approximately 80 million prevalent cases of CLBP across the 7MM, and this number is projected to increase between 2020 and 2034. DelveInsight estimates that in 2023, diagnosed prevalent cases of CLBP in the US accounted for about 45% of the total in the 7MM, with a concerning trend indicating a future rise in diagnosed cases. In 2023, there were approximately80 millionprevalent cases of CLBP across the 7MM, and this number is projected to increase between 2020 and 2034...
PR Newswire
16/06/2025

SciBase resolves on a directed share issue of SEK 19 million and announces its…

"We are very proud and pleased with both the previously announced collaboration agreement with Castle Biosciences and the fact that they are also becoming a major shareholder in SciBase. We believe this is the best outcome for SciBase and our shareholders, and we can now reach the market faster with new indications and continue to pursue our chosen strategy. In addition to Castle Biosciences, we are also very pleased to further strengthen our ownership base through an increased engagement…
PR Newswire
16/06/2025

Occupational Health Market to Reach USD 8,453.96 million By 2032, Growing At An…

Browse the report and understand how it can benefit your business strategy - https://www.credenceresearch.com/report/occupational-health-market Browse the report and understand how it can benefit your business strategy -https://www.credenceresearch.com/report/occupational-health-market Key Growth Determinants – Occupational Health Market Rising Focus on Workplace Wellness and Preventive Healthcare Organizations across sectors are increasingly prioritizing employee...
PR Newswire
16/06/2025

C-Path's New Paper in Nature Reviews Drug Discovery Highlights How to Maximize…

"This work emphasizes the urgency—and feasibility—of building globally coordinated, cross-sector efforts to drive innovation for patients who have long been underserved," said C-Path Vice President of Global Affairs Cécile Ollivier. "By aligning stakeholders and lowering technical and regulatory barriers, we can reshape the drug development landscape." "This work emphasizes the urgency—and feasibility—of building globally coordinated, cross-sector efforts to drive…
PR Newswire
16/06/2025

Casino Group: Information regarding buy-out of minority shareholders of Cnova…

Information regarding buy-out of minority shareholdersof Cnova N.V. – results of the voluntary transfer and implementation of squeeze-outParis, France / Amsterdam, the Netherlands, 16 June 2025 Reference is made to Casino’s press release regarding the Mandatory Buy-Out of the Cnova shares, (i) dated 17 October 2024, (ii) dated 12 February 2025, and (iii) dated 31 March 2025. Casino, Guichard-Perrachon S.A. (Euronext Paris: CO; ISIN: FR001400OKR3) (“ Casino ”) hereby announces the...
Nasdaq GlobeNewswire
16/06/2025

Regenerative Medicine Market to Hit USD 115.6 Billion by 2029 | Rising Demand in…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-27W15743/Global_and_India_Regenerative_Medicine_Market Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-27W15743/Global_and_India_Regenerative_Medicine_Market Major Factors Driving the Growth of Regenerative Medicine Market: The regenerative medicine market is experiencing transformative growth driven by advancements in cell therapy, tissue engineering, and biologics. It caters...
PR Newswire
16/06/2025

Patient Temperature Monitoring Market worth US$3.85 billion by 2032 with 6.7%…

Browse in-depth TOC on "Patient Temperature Monitoring Market" Browse in-depth TOC on "Patient Temperature Monitoring Market" 577 - Tables 57 - Figures 471 - Pages By application,the patient temperature monitoring market is categorized based on application into pyrexia/fever, hypothermia, blood transfusion, anesthesia, and other applications. Notably, the pyrexia/fever segment held the largest share in 2024 and is anticipated to exhibit the highest growth rate throughout...
PR Newswire
16/06/2025

Global Action to End Smoking Welcomes Nataliia Toropova as Chief Development…

"I'm honored to join Global Action, an organization that shares my own values of compassion for those who smoke and my vision of a world without smoking-related deaths," said Toropova. "I'm honored to join Global Action, an organization that shares my own values of compassion for those who smoke and my vision of a world without smoking-related deaths," said Toropova. Natasha will lead Global Action's efforts to expand its philanthropic reach by funding critical research and…
PR Newswire
16/06/2025

Vijay Dhawangale Honoured with Excellence in Healthcare Award at UK-India Health…

"It is a privilege to receive this award from Hon'ble Minister of Law and Justice, Shri Arjun Ram Meghwal, amidst a gathering of esteemed changemakers committed to advancing global health," said Vijay Dhawangale. "This honour reinforces our commitment to creating accessible, innovative, and sustainable healthcare solutions that reduce disparities and bring care closer to those who need it most." "It is a privilege to receive this award from Hon'ble Minister of Law and…
PR Newswire
16/06/2025

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 16, 2025 – Genmab A/S (Nasdaq: GMAB).On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025.The following transactions were executed under the program from June 9 to June 13, 2025: Trading PlatformNo...
Nasdaq GlobeNewswire
16/06/2025

Centessa Pharmaceuticals Announces Clearance of Investigational New Drug…

BOSTON and LONDON, June16, 2025(GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy volunteers. ORX142 is an investigational, novel, highly potent and selective OX2R agonist being developed for the treatment of select neurological and neurodegenerative disorders. ORX142 is the second drug...
Nasdaq GlobeNewswire
16/06/2025

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

LONDON and PHOENIX, June16, 2025(GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 2,400 ACUT shares in the open market. This brings his total holding to 6,502,400 shares. About AccuStem AccuStem is a clinical stage diagnostics company dedicated to...
Nasdaq GlobeNewswire
16/06/2025

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel…

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Growth strategyTEL AVIV, Israel and SHANGHAI, June16, 2025(GLOBE NEWSWIRE) -- Teva...
Nasdaq GlobeNewswire
16/06/2025

Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel…

The randomized, double-blind, placebo-controlled single- and multiple-ascending-dose (SAD/MAD) trial (ClinicalTrials.gov Identifier: NCT06537817) was conducted at CMAX Clinical Research in Adelaide, Australia. A total of 80 participants were dosed across 10 cohorts. The primary objectives of the trial were safety and tolerability, with secondary endpoints assessing pharmacokinetics (PK) and pharmacodynamics (PD. HT-4253 was generally well tolerated across all dose levels, with no serious adverse…
PR Newswire
16/06/2025

WuXi AppTec Recognized by Extel 2025 Asia Executive Team Rankings with Top…

Notably, WuXi AppTec achieved first-place rankings in the Healthcare, Pharma & Biotech sector in the following categories: "Best CEO," "Best CFO," "Best Company Board," "Best IR Program" and "Best ESG Program." This recognition underscores how WuXi AppTec's unique Contract Research, Development and Manufacturing Organization (CRDMO) model continues to drive sustainable business growth and enable the industry, patients and customers, creating…
PR Newswire
16/06/2025
Altri  Comunicati